Document Detail

Efalizumab in the treatment of discoid lupus erythematosus.
MedLine Citation:
PMID:  17638731     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Discoid lupus erythematosus is a chronic inflammatory condition in which the pathogenesis and the role of cell-mediated immunity remains unclear. Currently, the most effective treatments for severe disease are thalidomide, methotrexate, and cyclosporin, although the evidence for this is limited. Efalizumab is a monoclonal antibody directed against CD11a, the alpha-subunit of the leukocyte-functioning antigen 1, with a current license for use in psoriasis. Because discoid lupus erythematosus is known to be predominantly T-cell mediated, our aim was to use efalizumab as a T-cell modulator in patients with recalcitrant disease. OBSERVATIONS: Thirteen patients received efalizumab, with treatment responses varying from good to excellent in 12 of 13 patients. There was a significant reduction in the cutaneous lupus activity and severity score (CLASS) score after therapy with efalizumab (P = .002). CONCLUSIONS: We have presented efalizumab as a novel alternative treatment for patients with difficult discoid lupus erythematosus. The response to treatment in 12 patients was very encouraging, with the mean time to response being 5.5 weeks. However, patient numbers were small, and many remain in the early stages of therapy. A prospective randomized study with a long-term follow-up is required, especially in light of recent findings to evaluate both the effectiveness and safety profile of this monoclonal antibody.
Naila Usmani; Mark Goodfield
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of dermatology     Volume:  143     ISSN:  0003-987X     ISO Abbreviation:  Arch Dermatol     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-19     Completed Date:  2007-08-23     Revised Date:  2008-03-17    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  873-7     Citation Subset:  AIM; IM    
Department of Dermatology, Leeds General Infirmary, Great George St, Leeds LS1 3EX, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage,  therapeutic use*
Antigens, CD11*
Injections, Subcutaneous
Lupus Erythematosus, Discoid / drug therapy*,  pathology
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD11; 0/efalizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Breaking strength of barbed polypropylene sutures: rater-blinded, controlled comparison with nonbarb...
Next Document:  Dendritic cells in pigmented basal cell carcinoma: a relevant finding by reflectance-mode confocal m...